Shih-Hsin Wu Lawrence, Su Chun-Lin, Chen Ellson
Vita Genomics, Inc., 7Fl. No.6, Sec.1, Jungshing Rd., Wugu Shiang, Taipei, 248 Taiwan.
Pharmacogenomics. 2007 Jun;8(6):669-73. doi: 10.2217/14622416.8.6.669.
Vita Genomics, Inc., centered in Taiwan and China, aims to be a premier genomics-based biotechnological and biopharmaceutical company in the Asia-Pacific region. The company focuses on conducting pharmacogenomics research, in vitro diagnosis product development and specialty contract research services in both genomics and pharmacogenomics fields. We are now initiating a drug rescue program designed to resurrect drugs that have failed in the previous clinical trials owing to low efficacies. This program applies pharmacogenomics approaches using biomarkers to screen subsets of patients who may respond better or avoid adverse responses to the test drugs. Vita Genomics, Inc. has envisioned itself as an important player in the healthcare industry offering advanced molecular diagnostic products and services, revolutionizing thedrug-development process and providing pharmacogenomic solutions.
维塔基因组学公司总部位于中国台湾和中国大陆,旨在成为亚太地区领先的基于基因组学的生物技术和生物制药公司。该公司专注于开展药物基因组学研究、体外诊断产品开发以及基因组学和药物基因组学领域的专业合同研究服务。我们目前正在启动一项药物拯救计划,旨在复活那些因疗效不佳而在先前临床试验中失败的药物。该计划应用药物基因组学方法,利用生物标志物筛选出可能对受试药物反应更好或避免出现不良反应的患者亚组。维塔基因组学公司将自己设想为医疗保健行业的重要参与者,提供先进的分子诊断产品和服务,彻底改变药物开发过程并提供药物基因组学解决方案。